JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.
作者信息
Khan Sujoy, Durairaj Senthil
机构信息
Department of Immunology and Allergy, Hull University Teaching Hospitals NHS Trust, Queen's Center, Castle Hill Hospital, Cottingham, United Kingdom,
Department of Hematology and Hemato-Oncology, Hull University Teaching Hospitals NHS Trust, Queen's Center, Castle Hill Hospital, Cottingham, United Kingdom.
出版信息
Int Arch Allergy Immunol. 2020;181(7):563-564. doi: 10.1159/000508750. Epub 2020 May 26.
Abstract
摘要
相似文献
1
JAK Inhibition with Methotrexate as Treatment for COVID-19 Is a Double-Edged Sword.
Int Arch Allergy Immunol. 2020;181(7):563-564. doi: 10.1159/000508750. Epub 2020 May 26.
2
Low dose radiation therapy for COVID-19 pneumonia: A double-edged sword.
Radiother Oncol. 2020 Jun;147:224-225. doi: 10.1016/j.radonc.2020.04.026. Epub 2020 Apr 20.
3
Response to: Low dose radiation therapy for COVID-19 pneumonia a double-edged sword.
Radiother Oncol. 2020 Jun;147:226. doi: 10.1016/j.radonc.2020.04.042. Epub 2020 May 7.
4
Letter to the Editor: Social Media Is a Double-Edged Sword in the COVID-19 Pandemic.
J Korean Med Sci. 2020 Jul 27;35(29):e270. doi: 10.3346/jkms.2020.35.e270.
5
Corticosteroid use for 2019-nCoV infection: A double-edged sword.
Infect Control Hosp Epidemiol. 2020 Oct;41(10):1244-1245. doi: 10.1017/ice.2020.165. Epub 2020 Apr 23.
6
The Double-Edged Sword of Iranian Social Media Against COVID-19.
Prehosp Disaster Med. 2020 Aug;35(4):468-469. doi: 10.1017/S1049023X20000722. Epub 2020 May 21.
7
Granulocyte colony-stimulating factors (G-CSF) and Covid-19: a double-edged sword?
Infez Med. 2020 Sep 1;28(3):459-460.
8
COVID-19 and Racism-a double edged dagger.
Lancet Diabetes Endocrinol. 2020 Aug;8(8):649. doi: 10.1016/S2213-8587(20)30243-6. Epub 2020 Jul 10.
9
The double edged interferon riddle in COVID-19 pathogenesis.
Crit Care. 2020 Nov 1;24(1):631. doi: 10.1186/s13054-020-03337-z.
10
Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19.
Int Arch Allergy Immunol. 2020;181(8):648-649. doi: 10.1159/000509198. Epub 2020 Jun 12.
引用本文的文献
1
DHFR Inhibitors Display a Pleiotropic Anti-Viral Activity against SARS-CoV-2: Insights into the Mechanisms of Action.
Viruses. 2023 May 9;15(5):1128. doi: 10.3390/v15051128.
2
Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.
J Med Virol. 2022 Apr;94(4):1523-1534. doi: 10.1002/jmv.27482. Epub 2021 Dec 13.
3
Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis.
Sci Rep. 2021 Nov 8;11(1):21872. doi: 10.1038/s41598-021-01410-3.
4
Cancer vs. SARS-CoV-2 induced inflammation, overlapping functions, and pharmacological targeting.
Inflammopharmacology. 2021 Apr;29(2):343-366. doi: 10.1007/s10787-021-00796-w. Epub 2021 Mar 15.
5
COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.
Front Oncol. 2021 Jan 8;10:599502. doi: 10.3389/fonc.2020.599502. eCollection 2020.
6
The interplay between inflammatory pathways and COVID-19: A critical review on pathogenesis and therapeutic options.
Microb Pathog. 2021 Jan;150:104673. doi: 10.1016/j.micpath.2020.104673. Epub 2020 Dec 2.
7
Combination of JAKinibs with Methotrexate or Anti-Cytokine Biologics in Patients with Severe COVID-19.
Int Arch Allergy Immunol. 2020;181(8):648-649. doi: 10.1159/000509198. Epub 2020 Jun 12.
本文引用的文献
1
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
Lancet Rheumatol. 2020 Jun;2(6):e325-e331. doi: 10.1016/S2665-9913(20)30127-2. Epub 2020 May 7.
2
Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis.
Cell Host Microbe. 2020 Jul 8;28(1):117-123.e1. doi: 10.1016/j.chom.2020.05.007. Epub 2020 May 14.
3
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
Int Arch Allergy Immunol. 2020;181(6):467-475. doi: 10.1159/000508247. Epub 2020 May 11.
4
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
5
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.
Br J Dermatol. 2020 Aug;183(2):373-374. doi: 10.1111/bjd.19158. Epub 2020 May 28.
6
COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
Nat Rev Immunol. 2020 May;20(5):271-272. doi: 10.1038/s41577-020-0312-7.
7
Functional exhaustion of antiviral lymphocytes in COVID-19 patients.
Cell Mol Immunol. 2020 May;17(5):533-535. doi: 10.1038/s41423-020-0402-2. Epub 2020 Mar 19.
8
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.
Nat Rev Drug Discov. 2017 Dec 28;17(1):78. doi: 10.1038/nrd.2017.267.
9
How I treat CNS lymphomas.
Blood. 2013 Oct 3;122(14):2318-30. doi: 10.1182/blood-2013-06-453084. Epub 2013 Aug 20.
Zotero 插件